Of the many pro-inflammatory mediators secreted during CRS in patients receiving CAR T cell therapy, interleukin-6 (IL-6) appears to be the most prominent, and is secreted by activated endothelial cells (Levstek et al., 2024). This evidence concerns the gene IL6 and congenital rubella syndrome.